Seattle Children’s announces that the first patient in a cellular immunotherapy Phase 1 cancer trial has had a positive response to T-cell therapy. The patient had experienced a second relapse earlier this year, could no longer be treated with chemotherapy, and had less than a 20% chance of survival.
“At this time, we do not detect any leukemia cells,” said Rebecca Gardner, MD, principal investigator for the clinical trial. The next step for the patient is a stem cell transplant, with the aim of clearing the cancer from her body. It was the goal of immunotherapy to get her to this stage. T cell immunotherapy holds the promise of revolutionizing cancer treatment, eliminating the necessity for and adverse side effects of chemotherapy and radiation.
